The panel of primary mouse leukemias described here are novel reagents for investigating the effects of restoring WT Kras expression on fitness and for interrogating K-Ras protein dimerization and other candidate molecular mechanisms of growth inhibition [42, 43]. This evidence concerns the gene KRAS and leukemia.